Current perspectives on Streptococcus pneumoniae antibiotic resistance, with particular reference to isolates from Spain

Clinical Pulmonary Medicine

Volumn 12, Issue 4, 2005, Pages 210-219

  Aspa, Javier ^a   Rajas, Olga ^a   De Castro, Felipe Rodríguez ^b   Torres, Antoni ^c  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Antimicrobial resistance; Pneumococcal pneumonia; S pneumoniae

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; ERYTHROMYCIN; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATE; DRUG MEGADOSE; DRUG SURVEILLANCE PROGRAM; DRUG USE; HUMAN; LOBAR PNEUMONIA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; OUTPATIENT CARE; PENICILLIN RESISTANCE; PRACTICE GUIDELINE; REVIEW; SEROTYPE; SPAIN; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

EID: 23244458832     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cpm.0000171507.28715.67     Document Type: Review

References (107)

1. Pasteur L. Note sur la maladie nouvelle provoquée par la salive d'un enfant mort de la rage. Bull Acad Méd (Paris) [series 2]. 1881;10:94-103.
2. Sternberg G. A fatal form of septicaemia in the rabbit, produced by the subcutaneus injection of human saliva. Ann Rep Natl Board Health. 1881;3:87-108.
3. Nuorti JP, Butler JC, Crutcher JM, et al. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med. 1998;338:1861-1868.
4. Garau J. Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis. 2002;2:404-415.
5. Buckingham SC, Davis Y, English BK. Pneumococcal susceptibility to meropenem in a mid-south children's hospital. South Med J. 2002;95: 1293-1296.
6. Aspa J, Rajas O, Rodriguez de Castro F, et al. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis. 2004;38:787-798.
7. National Committee for Clinical Laboratory Standards (2002). Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement: Document M100-S12. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002.
8. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother. 1996;40:1817-1824.
9. Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother. 1991;35:1267-1272.
10. Montanari MP, Mingoia M, Giovanetti E, et al. Differentiation of resistance phenotypes among erythromycin-resistant pneumococci. J Clin Microbiol. 2001;39:1311-1315.
11. Johnston NJ, De Azavedo JC, Kellner JD, et al. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1998;42:2425-2426.
12. Pallares R, Fenoll A, Linares J. The epidemiology of antibiotic resistance in Streptococcus pneumoniae and the clinical relevance of resistance to cephalosporins, macrolides and quinolones. Int J Antimicrob Agents. 2003;22(suppl 1):S15-24.
13. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997;61:377-392.
14. Janoir C, Zeller V, Kitzis MD, et al. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother. 1996;40:2760-2764.
15. Munoz R, De La Campa AG. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenorype. Antimicrob Agents Chemother. 1996;40:2252-2257.
16. Fleming A. On the antibacterial action of culture of a penicillium, with special reference to their use in isolation of H. influenzae. Br J Exp Pathol. 1929;10:226-236.
17. Eriksen K. Studies on induced resistance to penicillin in a pneumococcus type 1. Acta Pathol Microbiol Scan. 1945;22:398-405.
18. Schmidt LHSC. Development of resistance to penicillin by pneumococci. Proc Soc Exp Biol Med. 1943;53:353-357.
19. García Rodríguez JA. Resistencias bacterianas ¿donde estamos? ¿hacia donde vamos? In: Picazo JJ, Bouza E, eds. Infección 1999. Bilbao; 1999:286-326.
20. Kislak JW, Razavi LM, Daly AK, et al. Susceptibility of pneumococci to nine antibiotics. Am J Med Sci. 1965;250:261-268.
21. Hansman D. A resistant pneumococcus [letter]. Lancet. 1967;2:264-265.
22. Appelbaum PC, Bhamjee A, Scragg JN, et al. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet. 1977;2: 995-997.
23. Finland M. Increased resistance in the pneumococcus. N Engl J Med. 1971;284:212-214.
24. Hansman D, Glasgow H, Sturt J, et al. Increased resistance to penicillin of pneumococci isolated from man. N Engl J Med. 1971;284:175-177.
25. Hansman D, Glasgow HN, Sturt J, et al. Pneumococci insensitive to penicillin. Nature. 1971;230:407-408.
26. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 1992;15:77-83.
27. Martínez-Beltrán JC. Mecanismos de resistencia a los antimicrobianos en Gram-positivos. Rev Clin Esp. 1994;803-813.
28. Appelbaum PC. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis. 2002;34:1613-1620.
29. Felmingham D, Gruneberg RN. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother. 2000;45:191-203.
30. Empey PE, Jennings HR, Thornton AC, et al. Levofloxacin failure in a patient with pneumococcal pneumonia. Ann Pharmacother. 2001;35: 687-690.
31. Jones RN. The impact of antimicrobial resistance: changing epidemiology of community-acquired respiratory-tract infections. Am J Health Syst Pharm. 1999;56:S4-11.
32. Davies T, Goering RV, Lovgren M, et al. Molecular epidemiological survey of penicillin-resistant Streptococcus pneumoniae from Asia, Europe, and North America. Diagn Microbiol Infect Dis. 1999;34: 7-12.
33. McDougal LK, Facklam R, Reeves M, et al. Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States. Antimicrob Agents Chemother. 1992;36:2176-2184.
34. Jorgensen JH, Doern GV, Maher LA, et al. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumonias in the United States. Antimicrob Agents Chemother. 1990;34:2075-2080.
35. Barry AL, Pfaller MA, Fuchs PC, et al. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993. Antimicrob Agents Chemother. 1994;38:2419-2425.
36. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med. 1995; 333:481-486.
37. Doern GV, Brueggemann A, Holley HP Jr, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996;40:1208-1213.
38. Ballow CH, Jones RN, Johnson DM, et al. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA: SPAR Study Group. Diagn Microbiol Infect Dis. 1997;29:173-186.
39. Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother. 2001;45:1721-1729.
40. Doern GV, Pfaller MA, Kugler K, et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis. 1998;27:764-770.
41. Centers for Disease Control and Prevention. Geographic variation in penicillin resistance in Streptococcus pneumoniae: selected sites, United States, 1997. MMWR Morb Mortal Wkly Rep. 1999;48:656-661.
42. Jacobs MR. Drug-resistant Streptococcus pneumoniae: rational antibiotic choices. Am J Med. 1999;106:19S-25S.
43. Pfaller MA, Jones RN, Doern GV, et al. Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 1999;33: 283-297.
44. Marchese A, Schito GC. Resistance patterns of lower respiratory tract pathogens in Europe. Int J Antimicrob Agents. 2000;16(suppl 1): S25-29.
45. Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. J Antimicrob Chemother. 2000;46(suppl T1):3-9.
46. The European Antimicrobial Resistance System (EARSS). Available at: http://www.earss.rivm.nl/.
47. European Surveillance of Antimicrobial Consumption. ESAC. Available at: http://www.ua.ac.be/ESAC.
48. National Committee for Clinical Laboratory Standards (2000). Performance Standards for Antimicrobial Susceptibility Testing: Tenth Informational Supplement, M100-S10. Wayne, PA: National Committee for Clinical Laboratory Standards; 2000.
49. National Committee for Clinical Laboratory Standards (1999). Performance Standards for Antimicrobial Susceptibility Testing: Ninth Informational Supplement, M100-S9. Wayne, PA: National Committee for Clinical Laboratory Standards; 2000.
50. Bedos JP, Chevret S, Chastang C, et al. Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey. Clin Infect Dis. 1996;22:63-72.
51. Baddour LM, Smith EA. Multidrug resistance among Streptococcus pneumoniae isolated at a university hospital in eastern Tennessee. Clin Infect Dis. 1999;29:224-225.
52. Fenoll A, Jado I, Vicioso D, et al. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990 to 1996). J Clin Microbiol. 1998;36:3447-3454.
53. Casal J. Antimicrobial susceptibility of Streptococcus pneumoniae: serotype distribution of penicillin-resistant strains in Spain. Antimicrob Agents Chemother. 1982;22:222-225.
54. Fenoll A, Martin Bourgon C, Munoz R, et al. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Rev Infect Dis. 1991;13:56-60.
55. Fenoll A, Asensio G, Jado I, et al. Antimicrobial susceptibility and pneumococcal serotypes. J Antimicrob Chemother. 2002;50(suppl S2): 13-19.
56. Linares J, Alonso T, Perez JL, et al. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics. J Antimicrob Chemother. 1992;30:279-288.
57. Linares J, Pallares R, Alonso T, et al. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clin Infect Dis. 1992;15:99-105.
58. Baquero F, Garcia-Rodriguez JA, Garcia de Lomas J, et al. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study: the Spanish Surveillance Group for Respiratory Pathogens. Antimicrob Agents Chemother. 1999;43:357-359.
59. Perez-Trallero E, Fernandez-Mazarrasa C, Garcia-Rey C, et al. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother. 2001;45:3334-3340.
60. National Committee for Clinical Laboratory Standards (1997). Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That Grow Aerobically, Fourth Ed: Approved Standard M7-A4. Wayne, PA: National Committee for Clinical Laboratory Standards.
61. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995;333:474-480.
62. Plouffe JF, Breiman RF, Facklam RR. Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention: Franklin County Pneumonia Study Group. JAMA. 1996;275:194-198.
63. Meynard JL, Barbut F, Blum L, et al. Risk factors for isolation of Streptococcus pneumoniae with decreased susceptibility to penicillin G from patients infected with human immunodeficiency virus. Clin Infect Dis. 1996;22:437-440.
64. Melander E, Molstad S, Persson K, et al. Previous antibiotic consumption and other risk factors for carriage of penicillin-resistant Streptococcus pneumoniae in children. Eur J Clin Microbiol Infect Dis. 1998;17:834-838.
65. Nava JM, Bella F, Garau J, et al. Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study. Clin Infect Dis. 1994;19:884-890.
66. Arnold KE, Leggiadro RJ, Breiman RF, et al. Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee. J Pediatr. 1996;128:757-764.
67. Henderson FW, Gilligan PH, Wait K, et al. Nasopharyngeal carriage of antibiotic-resistant pneumococci by children in group day care. J Infect Dis. 1988;157:256-263.
68. Pallares R, Gudiol F, Linares J, et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med. 1987;317:18-22.
69. Moreno S, Garcia-Leoni ME, Cercenado E, et al. Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clin Infect Dis. 1995;20:1195-1200.
70. Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis. 2001;32:701-707.
71. Garcia-Rey C, Aguilar L, Baquero F, et al. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J Clin Microbiol. 2002;40:159-164.
72. Granizo JJ, Aguilar L, Casal J, et al. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997). J Antimicrob Chemother. 2000;46:767-773.
73. Baquero F, Baquero-Artigao G, Canton R, et al. Antibiotic consumption and resistance selection in Streptococcus pneumoniae. J Antimicrob Chemother. 2002;50(suppl C):27-38.
74. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA. 1998;279:365-370.
75. Schrag SJ, Pena C, Fernandez J, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA. 2001;286:49-56.
76. Bronzwaer SL, Cars O, Buchholz U, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis. 2002;8:278-282.
77. Bremon AR, Ruiz-Tovar M, Gorricho BP, et al. Non-hospital consumption of antibiotics in Spain: 1987-1997. J Antimicrob Chemother. 2000;45:395-400.
78. Linares J, de la Campa AG, Pallares R. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med. 1999;341:1546-1547.
79. Molstad S, Lundborg CS, Karlsson AK, et al. Antibiotic prescription rates vary markedly between 13 European countries. Scand J Infect Dis. 2002;34:366-371.
80. European Surveillance of Antimicrobial Consumption. ESAC.
81. Price DB, Honeybourne D, Little P, et al. Community-acquired pneumonia mortality: a potential link to antibiotic prescribing trends in general practice. Respir Med. 2004;98:17-24.
82. Baquero F, Negri MC, Morosini MI, et al. Antibiotic-selective environments. Clin Infect Dis. 1998;27(suppl 1):S5-11.
83. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 2000;160:1399-1408.
84. Friedland IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J. 1995;14:885-890.
85. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 2000;90:223-229.
86. Choi EH, Lee HJ. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin Infect Dis. 1998;26:1346-1354.
87. Deeks SL, Palacio R, Ruvinsky R, et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae: the Streptococcus pneumoniae Working Group. Pediatrics. 1999;103:409-413.
88. Turett GS, Blum S, Fazal BA, et al. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis. 1999;29:321-327.
89. Buckingham SC, Brown SP, Joaquin VH. Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia. J Pediatr. 1998;132:174-176.
90. Dowell SF, Smith T, Leversedge K, et al. Failure of treatment of pneumonia associated with highly resistant pneumococci in a child. Clin Infect Dis. 1999;29:462-463.
91. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26: 1-10.
92. Ewig S, Ruiz M, Torres A, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med. 1999;159:1835-1842.
93. Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2000;30:520-528.
94. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis. 2003;37: 230-237.
95. Lujan M, Gallego M, Fontanals D, et al. Prospective observational study of bacteremic pneumococcal pneumonia: effect of discordant therapy on mortality. Crit Care Med. 2004;32:625-631.
96. Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis. 2000;31:613-615.
97. Kelley MA, Weber DJ, Gilligan P, et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis. 2000;31:1008-1011.
98. Waterer GW, Wunderink RG, Jones CB. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest. 2000;118:1839-1840.
99. Looks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis. 2002;35:556-564.
100. Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med. 2002;346:630-631.
101. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002;346:747-750.
102. Klugman KP. Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J Suppl. 2002;36: 3s-8s.
103. Ball P, Baquero F, Cars O, et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother. 2002;49:31-40.
104. Cornaglia G, Hryniewicz W, Jarlier V, et al. European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect. 2004;10:349-383.
105. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multi-center study. Clin Infect Dis. 1997;24:1052-1059.
106. Karlowsky JA, Thornsberry C, Jones ME, et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis. 2003;36:963-970.
107. Bauer T, Ewig S, Marcos MA, et al. Streptococcus pneumoniae in community-acquired pneumonia: how important is drug resistance? Med Clin North Am. 2001;85:1367-1379.